A Phase 1 Trial of RRx-001 in Combination With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Irinotecan (Primary) ; Nibrozetone (Primary) ; Temozolomide (Primary)
- Indications CNS cancer; Nervous system neoplasms; Solid tumours
- Focus Adverse reactions
- Acronyms PIRATE
- Sponsors EpicentRx
- 01 Aug 2024 Status changed from active, no longer recruiting to discontinued, due to low enrolment.
- 22 Mar 2024 Planned End Date changed from 1 Mar 2024 to 31 Dec 2024.
- 22 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 31 Dec 2024.